MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
MiNK Therapeutics, Inc.NASDAQ: INKT
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 4.8M shares rose 21.0% year over year, ahead of the +13.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 12.4% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +21.0% holds above the trailing-twelve-month pace of +13.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 4.27M USD
- Year-over-year change
- +10.5%
- 4-year CAGR
- +6.3%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.27M | +10.5% |
| FY2024 | 2024-12-31 | 3.86M | +12.4% |
| FY2023 | 2023-12-31 | 3.44M | +2.0% |
| FY2022 | 2022-12-31 | 3.37M | +0.6% |
| FY2021 | 2021-12-31 | 3.35M | — |
Weighted Avg Shares (Diluted) vs competitors
How INKT compares with its peers on the latest reported figures
- INKT's LTM Mar 2026 weighted avg shares (diluted) of 4.37M shares is the 8th highest of the 9 companies compared; the peer median is 29.8M shares.
- Its year-over-year change of +13.5% is the 7th highest of 9, against a peer median of +34.2%.
- Over three fiscal years its annual growth of +8.2% compares with a peer median of +25.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 64.9M | +81.6% | +39.7% | |
| LTM Jun 2026 | 47.65M | +7.1% | +17.5% | |
| LTM Mar 2026 | 35.13M | +38.4% | +40.5% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | 31.25M | -31.1% | +8.2% |
| LTM Mar 2026 | 28.35M | +14.4% | +33.9% | |
| LTM Mar 2026 | 26.06M | +115.3% | -31.2% | |
| LTM Mar 2026 | 7.87M | +30.1% | +63.7% | |
| LTM Mar 2026 | 4.37M | +13.5% | +8.2% | |
| LTM Mar 2026 | 827.01K | +51.8% | +7.8% | |
| Peer median (excluding INKT) | 29.8M | +34.2% | +25.7% | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Gross Profit | (77.96K) | (121.75K) | (204.62K) | (215.44K) | (181.75K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.97M | 23.12M | 15.49M | 6.34M | 5.76B |
| Selling, General & Admin | 4.56M | 7.71M | 7.43M | 4.1M | 6.73B |
| Operating Expenses | 18.53M | 30.83M | 22.72M | 10.43M | 12.31M |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| EBITDA | (27.7M) | (27.87M) | (22.25M) | (10.57M) | (12.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.61M) | (30.95M) | (22.92M) | (10.65M) | (12.49M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.43K | 253.32K | 463.26K | 172.57K | 180.25K |
| Interest Expense | 2.43M | 253.32K | 0 | 0 | 0 |
| Other Income / Expenses | (11.61M) | 2.96M | 463.25K | (134.56K) | (6.96K) |
| Income Before Tax | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.03) | (8.31) | (6.54) | (2.90) | (2.93) |
| EPS (Diluted) | (9.03) | (8.31) | (6.54) | (2.80) | (2.93) |
| Weighted Avg Shares | 3.35M | 3.37M | 3.44M | 3.74M | 4.27M |
| Weighted Avg Shares (Diluted) | 3.35M | 3.37M | 3.44M | 3.86M | 4.27M |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.